ClinicalTrials.Veeva

Menu

Panniculitis in Dermatomyositis (PANNICUL)

U

University Hospital, Strasbourg, France

Status

Enrolling

Conditions

Dermatomyositis
Panniculitis

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Adipose tissue involvement is rare in dermatomyositis. The occurrence of partial or diffuse lipodystrophy is a rare but well-characterized manifestation, particularly in juvenile forms of dermatomyositis. Panniculitis, on the other hand, is exceptional and rarely described in the literature, mostly in the form of clinical cases.

Panniculitis in dermatomyositis is exceptional. There are no validated diagnostic criteria or treatment recommendations. Treatment is based, by analogy, on the therapeutic strategy for lupus panniculitis and involves synthetic antimalarials combined with steroids and/or immunosuppressants.

The aim of this study is to describe panniculitis in dermatomyositis in order to determine whether there are clinical or histological characteristics that distinguish it from other causes of panniculitis, particularly panniculitis associated with lupus erythematosus.

Enrollment

20 estimated patients

Sex

All

Ages

1+ year old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject aged 1 year and older
  • With a confirmed diagnosis of dermatomyositis
  • With a confirmed diagnosis of panniculitis

Exclusion criteria

  • Panniculitis for which another cause has been established, particularly infectious and metabolic panniculitis

Trial contacts and locations

1

Loading...

Central trial contact

Dan LIPSKER, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems